Opinion
Video
Closing Thoughts and Key Takeaways on Small Cell Lung Cancer
Author(s):
In a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.
EP: 1.Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer
EP: 2.ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
EP: 3.cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
EP: 4.Examining 3-Year Update Data from the CASPIAN Trial
EP: 5.Predictors of Immunotherapy Response in Limited and Extensive SCLC
EP: 6.Overcoming Immunotherapy Resistance in Small Cell Lung Cancer
EP: 7.Examining the use of PD-L1 and tTMB in the CASPIAN Trial
EP: 8.Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
EP: 9.Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
EP: 10.DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
EP: 11.Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
EP: 12.Examining Key Data from DAREON-8
Now Viewing
EP: 13.Closing Thoughts and Key Takeaways on Small Cell Lung Cancer
Video content above is prompted by the following question:
- What are your final perspectives and insights on unmet needs and therapeutic advances in SCLC?
Related Videos
Related Content
